Introduction
Sodium-lithium countertransport (SLC) is a poorly understood membrane transport process in which increased activity has been related prospectively with the development of vascular disease. 1 Associations have been demonstrated with non-insulin dependent diabetes mellitus, 2 essential hypertension, [3] [4] [5] and risk of coronary artery disease. [6] [7] [8] The activity of SLC can be resolved into kinetic components of maximal turnover velocity (V max ) and substrate affinity (K m ). 1, 2, 9 Few studies have examined the inter-relationship of SLC kinetics and primary dyslipidaemia. Membrane cholesterol is known to influence transport processes 10 so in this study investigated the effects of severe hypercholesterolaemia in patients with heterozygous familial hypercholesterolaemia (FH) on SLC activity and kinetics. 
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؉ /L.RBC.hr; P ‫؍‬ 0.009 respectively). In multiple regression analysis, log normalised SLC activity correlated weakly with log triglyceride (␤ ‫؍‬ 0.225; P ‫؍‬ 0.06) and cholesterol (␤ ‫؍‬ ؊0.112 P ‫؍‬ 0.06). Log V max correlated with log triglyceride (␤ ‫؍‬ 0.307; P ‫؍‬ 0.02), and high-density lipoprotein (HDL) (␤ ‫؍‬ 0.74; P ‫؍‬ 0.03) whilst K m correlated with HDL (␤ ‫؍‬ 1.73; P Ͻ 0.001) and apoAI (␤ ‫؍‬ ؊1.76; P ‫؍‬ 0.0048), LDL (␤ ‫؍‬ ؊0.14; P ‫؍‬ 0.05), and creatine kinase (␤ ‫؍‬ 0.003; P ‫؍‬ 0.01). Cholesterol and triglyceride concentrations rather than insulin resistance seem to be the key features affecting the environmental alteration of sodium lithium countertransporter V max in patients with familial hypercholesterolaemia. Journal of Human Hypertension (2000) 14, 561-565
Methods

Subjects
The patients recruited for this study comprised patients under long-term follow-up for familial hypercholesterolaemia. Diagnosis was made on the basis of a raised low-density lipoprotein (LDL)-cholesterol (Ͼ5.5 mmol/L) and normal triglycerides (Ͻ2.50 mmol/L) and an autosomal dominant history of early onset (Ͻ50 years) of coronary heart disease or the presence of another affected direct related sib with similar LDL-cholesterol in the family according to the Simon Broome Register criteria. 11 Patients were divided clinically into definite FH and biochemical FH groups based on the presence or absence of tendon xanthomata. Full informed ethical consent was obtained in all cases. Patients were sampled on lipid-lowering drug therapy as it was deemed unethical to stop treatment for the 3-6 month period necessary to allow determination of baseline values for lipids and SLC activity. Lipid-lowering drug therapy comprised simvastatin in all cases except for two patients who received pravastatin.
Basic anthropometric data (height and weight) were collected. Blood pressure was measured manually by the same operator on three separate occasions 5 min apart. Alcohol and cigarette intake were ascertained by direct questioning. The status of patients with respect to coronary arterial disease was established by history of interventional cardiac procedures or previous events and admissions.
Age-and sex-matched controls were recruited from healthy volunteers attending Chelsea and Westminster Hospital. The control subjects had no history of coronary disease, hypertension, diabetes, hyperuricaemia or other disorders known to affect lipoprotein profiles. These patients were co-sampled with the study patients and underwent identical test and analyses.
Biochemical analysis
Fasting blood samples were collected from into a 10-ml EDTA vacutainer to give a final concentration of 1 mg/ml. Total cholesterol and cholesterol in subfractions were measured by the CHOD-PAP method on a Vitros 950 analyser (Johnson & Johnson, UK). Triglycerides and subfraction triglyceride content were measured after two-, five-and 10-fold dilution using a lipase method on the same analyser. In patients with triglycerides Ͻ4.5 mml/L LDL concentrations were determined by calculation using the Freidewald equation. Other biochemical parameters including urea and electrolytes, glucose, aspartate transaminase, bilirubin, gamma-glutamyl transferase, urate and creative kinase were measured were measured by standard methods on the Vitros 950 analyser.
Apolipoproteins A1, A2 and B 100 concentrations were determined by immunoturbidimetry on a Cobas Fara 2 analyser using Dako antisera. Lipoprotein (a) was determined by similar methods after pre-incubation of the sample with lipase and centrifugation. Plasma insulin was measured by ELISA using the Boehringer-Mannheim kit for an ES700 automated analyser with 10% cross-reactivity for pro-insulin and 4% for 22,23 des-pro-insulin. Measurements were validated with a Corning ACS method with lower cross-reactivity at a later date with no significant alteration in results. Insulin resistance was determined by calculation of the HOMA and beta cell indices.
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Measurement of sodium-lithium countertransport
Sodium-lithium countertransport was measured by established methods.
1,2,7-9 Erythrocytes were loaded with lithium for 3 h and aliquots were added to choline/sodium containing media. Loaded erythrocytes were incubated in 10 external media of differing sodium concentrations in the range 0-150 mM (0, 15, 30, 45, 60, 75, 90, 112.5, 129 and 150 mM). Isotonicity was maintained by appropriate amounts of choline chloride; incubation media included magnesium chloride (1 mM); glucose (10 mM), ouabain (0.1 mM), Tris-MOPS pH 7.4 at 37°C (10 mM). Aliquots were removed at 15, 30 and 45 min and used to determine the lithium efflux rate into the supernatant. The kinetic parameters maximal velocity (V max ) and sodium affinity (K m ) were derived from lithium efflux rates plotted against the lithium efflux/sodium concentration ratio in an Eadie-Hoffstee plot. Data were fitted by linear regression with K m was determined from the slope and V max from the y-intercept. Correlation coefficients of 0.98 were achieved in all cases. Mean interassay and intra-individual coefficients of variation based on triplicate analyses of 10 patients on 3-10 occasions for this method were 6.3% and 10.2% respectively.
Statistical methods
Results were analysed using a commercial spreadsheet and statistics packages (Microsoft Excel, Seattle, WA, USA and GB-STAT, Dynamic Microsystems, Silver Spring, MD, USA). The data were analysed using after natural logarithm transformation of non-Gaussian distributed data for triglycerides, insulin, HOMA and beta cell indices and lipoprotein (a). Success of transformation was assessed by tests of normality. Data were analysed by unpaired Student's t-test, correlation analysis, and ANOVA. Backward stepwise multiple linear regression was used to determine the factors influencing SLC kinetics using log transformed variables where appropriate. Population data were analysed by ANOVA when normally distributed and otherwise by the non-parametric Mann-Whitney U test. A P value of Ͻ0.05 was considered significant.
Results
Clinical data on the subjects are shown in Table 1 and biochemical data are presented in Table 2 . Significant differences were seen in total cholesterol, LDL-cholesterol, apolipoprotein B, lipoprotein (a) with respect to controls. Patients with FH had slightly but non-significantly raised blood pressure compared to controls. (P = 0.26). Cholesterol and LDL-cholesterol values were significantly different between definite and biochemical cases of FH. There were no significant differences between any other lipid parameters.
The activity and kinetic parameters of SLC could be normalised after log e transformation. Both activity (geometric means 0.172 vs 0.217 mmol Li + /L.RBC.hr; P = 0.016) and V max (geometric mean 0.237 vs 0.317 mmolLi + /L.RBC.hr; P = 0.009) were significantly reduced in patients with FH and the effect was independent of the presence of tendon xanthomata. SLC activity and V max correlated with Normally distributed data is tabulated as mean and standard deviation while non-normal data is shown as geometric mean and range. *P Ͻ 0.05; **P Ͻ 0.01; ***P Ͻ 0.001.
systolic blood pressure in all groups of patients (r 2 = 0.175; P = 0.02 and ␤ = 0.009; P = 0.05 in multiple regression analysis). Stepwise multiple regression analysis after exclusion of blood pressure demonstrated that activity was dependent on total cholesterol (␤ = −0.112; P = 0.06) and triglycerides (␤ = 0.225 P = 0.05). Resolution of activity into kinetic parameters showed that V max was dependent on In triglyceride (␤ = 0.307; P = 0.02) and high-density lipoprotein (HDL) (␤ = 0.74; P = 0.02) and correlated weakly with cholesterol (␤ = −0.119; P = 0.09). Sodium affinity (K m ) was strongly dependent on HDL (␤ = 1.73; P = Ͻ0.001), inversely with apoA1 (␤ = −1.76; P = 0.005) and weakly on creatine kinase activity (␤ = 0.003; P = 0.01). There was no correlation with any parameters related to insulin resistance: glucose, insulin, HOMA or beta cell function indices in this study.
Discussion
The kinetics of sodium-lithium countertransport which has been shown to correlate with cardiovascular risk factors particularly hypertension, the metabolic syndrome (insulin resistance), diabetes, ethnic origin and to be altered in patients with established coronary arterial disease. [1] [2] [3] [4] [5] [6] [7] [8] [9] 13, 14 Though many studies have been conducted on this transporter its exact mechanism remains obscure.
1 Some studies have suggested that SLC V max is altered by membrane triacylglycerols resulting in alterations of phospholipid profile and exposure of sulph-hydryl groups 9,15,16 yet in polygenic mixed hyperlipidaemic patients it has always been thought that the mechanism might involve insulin sensitivity rather than be related to triglyceride concentration. It has also been shown that SLC activity can be affected by the identity of fatty acids with a reduction in activity with the alpha-methylated fatty acids in Refsum's disease. 17 Membrane function has been shown to be affected by these fatty acids 18 and also by cholesterol. 10 The aims of this study were to investigate whether SLC kinetics were affected by severe hypercholesterolaemia in the absence of hypertension.
Our study shows that SLC activity is dependent on triglyceride and HDL concentrations as in pre-
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vious studies after removal of a strong correlation with blood pressure which is seen even in nonhypertensive patients. [1] [2] [3] [4] [5] [6] [7] [8] [9] However, our data do not show any relationship of SLC kinetic parameters with markers of insulin resistance. This relationship has been described as being absent in other normotensive populations. 16, 19 One previous study has examined SLC kinetics in patients (12 male, 36 female; average age 54.5 years) with familial hypercholesterolaemia. 20 In contrast to our study it included patients with a significantly increased systolic and diastolic blood pressures (systolic blood pressure = 146 ± 21 mm Hg; diastolic blood pressure = 88 ± 16 mm Hg) compared to controls. Patients had higher LDL-cholesterol values (6.1 ± 1.6 mmol/L) and triglyceride concentrations (3.7 mmol/L) compared to our series and there was no difference in SLC activity between controls and patients with FH. SLC activity and V max were reduced in patients with FH compared to controls in our study but given the elevation of SLC activity seen with hypertension 1 the difference between the two studies could reflect the relative incidence of hypertension in the two populations studied. The patients in this study were treated with hydroxymethyl-glutaryl-CoA reductase inhibitors (statins) which have been previously shown not to affect SLC activity. 21 Some other lipid-lowering therapies have effects on SLC activity proportional to their effect on triglycerides. 22 Other methods of LDL reduction by apheresis 23 which removes others lipoproteins as well as LDL and thyroid replacement therapy for hypothyroidism which has profound other metabolic effects on other pathways besides LDL metabolism also have effects on SLC activity. 24 As in our series, the previous study 20 showed a correlation of triglyceride with In SLC V max in all patients, but the only blood pressure correlation was with diastolic pressures (r 2 = 0.171; P = 0.10). Again this could reflect differences in patient selection. All other parameters showed no correlation with SLC kinetics. A weak correlation with body mass index (r 2 = 0.211; P = 0.06) was also observed in that study but not in this one. In our study SLC activity and V max were reduced in patients with FH compared to controls and the effect was positively associated with triglycerides and HDL, and inversely with cholesterol, LDL-cholesterol or apolipoprotein A1 or B concentration and showed no relation to the HOMA index of insulin resistance. This suggests that that elevated cholesterol, in the absence of hypertension, may reduce SLC activity through a mechanism that is independent of insulin resistance. In previous studies we have shown a negative correlation of HDL with SLC V max in normolipaemic caucasians on multiple regression analysis and but that occurred in the absence of additional data on apoliporotein A1 concentrations.
14 Modelling with HDL alone gave similar results to the data on HDL: apolipoprotein A1 ratio and apolipoprotein A1 combined indicating a possible difference between normotensive normolipidaemic patients and normotensive FH patients.
It has been noted in patients with homozygous FH that thickness of Achilles tendon xanthomata correlated to lipoprotein lipase (LPL) activity. 25 There is little data as yet on LPL activity in patients with heterozygous FH but a similar correlation might be expected. In heterozygous FH patients triglycerides, tendon xanthomata and prognosis correlate with the asparate 9 → asparagine (D9N) or asparagine 291 → serine (N291S) polymorphisms in LPL. 26, 27 However, in this study there was no difference in SLC kinetics between patients with or without tendon xanthomata.
This study shows that both serum cholesterol and triglyceride affect SLC activity and V max in patients with FH with the strongest effects being seen on maximal velocity for triglycerides and cholesterol and HDL for sodium affinity. 
